Not yet recruiting
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
NCT07725484· Phase 3· Shanghai Zhongshan Hospital· Source
Contact: Kangyu Chen
Not yet recruiting
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: HongLiang HE, doctor
Recruiting
ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase
NCT07751536· Shuanghu Yuan· Source
Contact: ShuangHu Yuan
Recruiting
China Metastatic Liver Cancer Clinical Registry Cohort Database
NCT07602504· Anhui Provincial Hospital· Source
Contact: Jizhou Wang
Recruiting
Adaptive DBS for PD
NCT07635823· Beijing Pins Medical Co., Ltd· Source
Contact: Chaoshi Niu (principal investigator)
Recruiting
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
NCT07444307· Phase 1· Hangzhou Qihan Biotech Co., Ltd.· Source
Contact: Zhu Chen, PhD
Recruiting
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235· Phase 4· Shanghai Zhongshan Hospital· Source
Contact: Wei Wang
Recruiting
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
NCT07282353· Phase 3· Cascade Pharmaceuticals, Inc· Source
Contact: He Hongliang
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650· Phase 1· Shanghai Henlius Biotech· Source
Contact: Henlius
Recruiting
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
NCT07187440· Takeda· Source
Contact: Kangyu Chen (principal investigator)
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· Phase 3· BioNTech SE· Source
Active, not recruiting
A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.
NCT07557004· Phase 1· Nanjing Sanhome Pharmaceutical, Co., Ltd.· Source
Not yet recruiting
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
NCT07083739· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Changcheng Zheng, Doctor
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
NCT06900920· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Changcheng Zheng, Doctor
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575· Phase 3· Jazz Pharmaceuticals· Source
Contact: Clinical Trial Disclosure & Transparency
Active, not recruiting
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source
Recruiting
Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients
NCT06315231· Phase 2· Simcere Pharmaceutical Co., Ltd· Source
Contact: Jiong Shi, Doctor
Recruiting
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
NCT06092047· Early phase 1· PersonGen BioTherapeutics (Suzhou) Co., Ltd.· Source
Contact: Xingbing Wang, MD
Active, not recruiting
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
NCT05896124· Phase 2· Cascade Pharmaceuticals, Inc· Source
Active, not recruiting
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
NCT05896137· Phase 2· Cascade Pharmaceuticals, Inc· Source
Recruiting
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
NCT05866029· Peking Union Medical College Hospital· Source
Contact: Chao Chen
Active, not recruiting
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
NCT06443684· Shanghai Chest Hospital· Source
Recruiting
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505· Phase 2· Guangdong Association of Clinical Trials· Source
Contact: Li Ke
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224· Phase 3· Shanghai Henlius Biotech· Source
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205· Phase 1/2· Allist Pharmaceuticals, Inc.· Source
Contact: Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., Ltd
Active, not recruiting
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
NCT04944043· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305· Phase 4· Fudan University· Source
Contact: Xiaopeng Ma
Active, not recruiting
A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)
NCT05058040· Phase 4· Green Valley (Shanghai) Pharmaceuticals Co., Ltd.· Source
Active, not recruiting
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499· Phase 1/2· Klus Pharma Inc.· Source
Active, not recruiting
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022· Phase 1/2· Dizal Pharmaceuticals· Source